A trial to determine how nanatinostat is absorbed, modified, and removed from the body and the amount of nanatinostat that becomes available to the body in patients with cancers that is very large or has spread to other parts of the body

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508184-74-00

Acronym

VT3996-102

Enrollment

Registered

2024-02-12

Start date

2024-02-28

Completion date

2025-01-15

Last updated

2024-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced cancer

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026